IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.108
EU - Europa 9.929
AS - Asia 9.166
SA - Sud America 2.097
AF - Africa 969
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 19
Totale 47.317
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.122
SG - Singapore 4.433
CN - Cina 3.309
IE - Irlanda 2.646
IT - Italia 2.534
UA - Ucraina 2.394
BR - Brasile 1.830
CA - Canada 874
RU - Federazione Russa 697
CI - Costa d'Avorio 679
VN - Vietnam 342
SE - Svezia 315
DE - Germania 313
IN - India 266
GB - Regno Unito 247
KR - Corea 220
SN - Senegal 139
FI - Finlandia 117
FR - Francia 111
AR - Argentina 96
CH - Svizzera 88
NL - Olanda 86
UZ - Uzbekistan 79
PL - Polonia 71
BD - Bangladesh 70
MX - Messico 67
AT - Austria 61
JP - Giappone 60
EC - Ecuador 52
TR - Turchia 52
ZA - Sudafrica 52
CZ - Repubblica Ceca 50
IQ - Iraq 48
BE - Belgio 47
HK - Hong Kong 45
GR - Grecia 44
ES - Italia 36
LB - Libano 36
MA - Marocco 29
CO - Colombia 28
VE - Venezuela 26
ID - Indonesia 25
PK - Pakistan 23
AU - Australia 20
IR - Iran 20
EU - Europa 18
IL - Israele 18
SA - Arabia Saudita 17
CL - Cile 16
PY - Paraguay 16
JO - Giordania 15
TN - Tunisia 14
BO - Bolivia 13
EG - Egitto 13
KE - Kenya 13
AE - Emirati Arabi Uniti 12
PE - Perù 12
AZ - Azerbaigian 11
BG - Bulgaria 11
DO - Repubblica Dominicana 11
NG - Nigeria 11
RS - Serbia 11
DZ - Algeria 10
KZ - Kazakistan 10
LT - Lituania 9
NO - Norvegia 9
RO - Romania 8
NZ - Nuova Zelanda 7
PS - Palestinian Territory 7
UY - Uruguay 7
JM - Giamaica 6
NP - Nepal 6
TH - Thailandia 6
BH - Bahrain 5
CR - Costa Rica 5
KW - Kuwait 5
OM - Oman 5
PH - Filippine 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
AL - Albania 4
BB - Barbados 4
MY - Malesia 4
HN - Honduras 3
LU - Lussemburgo 3
PA - Panama 3
PT - Portogallo 3
AM - Armenia 2
AO - Angola 2
BF - Burkina Faso 2
EE - Estonia 2
HU - Ungheria 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NI - Nicaragua 2
SV - El Salvador 2
BA - Bosnia-Erzegovina 1
BW - Botswana 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
Totale 47.297
Salva come PNG Salva come JPEG
Città #
Dallas 5.100
Santa Clara 2.887
Singapore 2.695
Jacksonville 2.636
Dublin 2.628
Chandler 2.134
Boardman 1.117
Chicago 949
Catania 897
Nanjing 751
Cambridge 720
Andover 716
Lawrence 715
Abidjan 677
Toronto 646
Ashburn 613
Hefei 501
Houston 499
Des Moines 423
San Mateo 386
Beijing 315
Nanchang 262
Wilmington 261
Civitanova Marche 229
Los Angeles 223
Seoul 220
Saint Petersburg 182
Shenyang 180
Hebei 176
Ottawa 148
Jiaxing 147
São Paulo 142
Dakar 138
Changsha 134
Florence 133
Tianjin 109
Rome 97
Grafing 96
Council Bluffs 92
Kochi 92
New York 91
Ho Chi Minh City 88
Dong Ket 87
Munich 71
Milan 68
Palermo 65
Hanoi 63
Brooklyn 62
Moscow 62
Seattle 61
Washington 57
Rio de Janeiro 51
The Dalles 51
Tokyo 49
San Francisco 48
Columbus 46
Boston 45
Hangzhou 45
Belo Horizonte 42
Brussels 42
Hong Kong 42
Turku 42
Den Haag 39
Helsinki 38
Norwalk 37
Lappeenranta 36
Kunming 35
Stockholm 35
Johannesburg 34
Warsaw 34
Montreal 33
Falls Church 32
Pune 32
Chennai 31
Jinan 29
Tashkent 29
Bremen 28
Phoenix 27
Porto Alegre 27
Brasília 26
Mumbai 26
Guangzhou 25
Curitiba 24
Atlanta 22
Bari 22
Brno 22
Messina 22
Mexico City 21
Ann Arbor 20
Campinas 20
Guayaquil 20
Liberty Lake 20
Naples 20
Ankara 19
Denver 18
Fortaleza 18
Frankfurt Am Main 18
London 18
Redwood City 18
Zhengzhou 18
Totale 33.337
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 243
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 232
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 176
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 175
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 174
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 155
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 155
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 149
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 143
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 137
Il Rasario. Semeiotica medica 134
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 128
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 128
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 121
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 120
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 120
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 120
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 119
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 119
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 119
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 118
Hedgehog signaling pathways in multiple myeloma 116
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 116
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 115
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 112
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 112
A snapshot of asparaginase-induced liver insufficiency. 110
Acute pre-hepatic portal thrombosis: diagnosis and therapy 109
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 109
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 108
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 108
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 107
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 107
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 107
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 106
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 105
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 105
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 105
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 104
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 104
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 104
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 104
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 103
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 103
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 103
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 102
Terapia del mieloma multiplo 102
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 102
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 102
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 101
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 101
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 101
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 101
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 100
A case of high-risk AML in a patient with advanced systemic mastocytosis 100
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 100
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 99
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 98
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 98
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 98
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 98
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 97
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 97
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 97
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 97
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 97
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 96
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 95
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 95
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 95
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 93
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 93
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 93
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 93
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 92
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 92
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 92
A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY 92
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 92
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 91
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 91
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 91
Bone turnover markers in patients with type 1 Gaucher disease 91
Angiogenesis in acute myeloid leukemia 90
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 90
Cementoplasty in the management of painful extraspinal bone metastases: our experience 90
Eventi avversi e trigger C12: Stroke in ospedale 90
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 89
Lymphoma of the cecum: a case report 88
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 88
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 87
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 87
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 87
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 86
ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA C.M.S 86
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 86
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 86
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 85
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 85
CD200 expression in patients with multiple myeloma: Another piece of the puzzle 85
Totale 10.817
Salva come PNG Salva come JPEG
Categoria #
all - tutte 189.395
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 189.395
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.962 0 0 0 81 1.175 67 540 13 470 8 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/20269.457 1.673 1.754 5.013 1.017 0 0 0 0 0 0 0 0
Totale 48.373